Application of silymarin in human and animal medicine
Lidia Radko 1  
More details
Hide details
Division of Toxicology and Environmental Protection, Department of Veterinary Pre-clinical Sciences, Faculty of Veterinary Medicine, Agricultural University, Lublin, Poland
Lidia Radko   

Division of Toxicology and Environmental Protection, Department of Veterinary Pre-clinical Sciences, Faculty of Veterinary Medicine, Agricultural University, ul. Akademicka 12, 20-033 Lublin, Poland
J Pre Clin Clin Res. 2007;1(1):22–26
Silymarin, the polyphenolic fraction from Milk Thistle (Silybum marianum) and its main component silybinin, are used almost exclusively for hepatoprotection in humans. Silymarin offers good protection in various toxic models of experimental liver diseases in laboratory animals. It effects, by antioxidative, anti-inflammatory, antifibrotic, anti-lipid peroxidative, membrane stabilizing and liver regenerating mechanisms. Its clinical applications in humans comprise therapy in alcoholic liver diseases, liver cirrhosis, Amanita mushroom poisoning, viral hepatitis, toxic and drug-induced liver diseases. Recognition of new silymarin derivatives opens new ways for its application in liver therapy. Silymarin application in veterinary medicine is also reviewed.
Morazzoni P, Bombardelli E: Silybum marianum (Carduus marianus). Fitoterapia 1995, 66, 3-42.
Křen V, Walterová D: Silybin and silymarin – new effects and applications. Biomed Papers 2005, 149 (1), 29-41.
Fraschini F, Demartini G, Esposti D: Pharmacology of silymarin. Clin Drug Invest. 2002; 22 (1), 51-65.
Filburn CR, Kettenacker R, Griffin DW: Bioavailability of a silybinphosphatidylcholine complex in dogs. J Vet Pharmacol Therap 2007, 30, 132-138.
Fernando A, Crocenzi Roma MG: Silymarin as a New Hepatoprotective agent in experimental cholestasis: New possibilities for an ancient medication. Current Medicinal Chemistry 2006, 13 (9), 1055-1074.
Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E: Pharmacokinetic studies on Idb 1016, a silybin-phosphatidylcholine complex (Siliphos®), in healthy human subjects Eur. J Drug Metab Pharmacokinet 1990, 15, 333-338.
Maheshwari H, Agarwal R, Patil C, Katare OP: Preparation and pharmacological evaluation of silibinin liposomes. Arzneimittelforschung 2003, 53, 420–427.
Abrol S, Trehan A, Katare OP: Formulation, characterization, and in vitro evaluation of silymarin loaded lipid microspheres. Drug Deliv. 2004, 11 (3), 185-191.
Pradhan SC, Girish C: Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res 2006, 124 (5), 491-504.
Sridar Ch., Goosen TC, Kent UM, Williams JA, Hollenberg PF: Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metabolizm and Disposition 2004, 32 (66), 587-594.
Zuber R, Modrianský M, Dvořák Z, Rohovský P, Ulrichová J, Šimánek V, Anzenbacher P: Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities Phytother. Res 2002, 16 (7), 632-638.
Jacobs PB, Dennehy C, Ramirez G, Sapp J, Lawrence VA: Milk thistle for the treatment of liver disease: A systematic review and meta-analysis Am J Med 2002, 113 (6), 506-515.
Kosina P, Maurel P, Ulrichová J, Dvořák Z: Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes. J Biochem Molecular Toxicology 2005, 19 (3), 149-153.
Kosina P, Kren V, Gebhardt R, Grambal F, Ulrichova J, Walterova D: Antioxidant properties of silybin glyco- sides. Phytother Res 2002, 16, S33–S39.
Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO: Hepatoprotective mechanism of silymarin; no evidence for involvement of cytochrome p 450 2E1. Chem Biol Interact 1994, 91 (1), 51-63.
Miller AL: Antioxidant flavonoids: Structure, function and clinical usage. Alt Med Rev 1996,1 (2),103-111.
Wisemann H: dietary influences on membrane function: Importance in protection against oxidative damage and disease. J Nutr Biochem 1996, 7, 2-5.
Muriel P, Mourelle M: Prevention by silymarin of membrane alterations in acute CCL4 liver damage. J Appl Toxicol 1990, 10 (4), 275–279.
Sonnenbichler J, Zetl I: Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog. Clin. Biol. Res. 1986, 213, 319-31.
Saller R, Meier R, Brignoli R: The use silymarin in the treatment of liver diseases. Drugs 2001, 61 (14), 2035-2063.
Dehmlow C, Erhard J. Goot HD: Inhbition of Kupffer cells as an explanation for the hepatoprotective properties of silibinin. Hepatology 1996, 23 (4), 749-754.
Saliou C, Rihn B, Cillard J, Okamoto T, Packer L: Selective inhibition of NF-κB activation by the flavonoid hepatoprotector silymarin in HepG2. FEBS Lett. 1998, 440, 8-12.
Johnson VJ, Osuchowski MF He Q, Sharma RP: Physiological responses to a natural antioxidant flavonoids mixture, silymarin, in BALB/c mice: II Alterations on thymic differentiation correlate with changes in c-myc gene expression. Planta Med 2002, 68 (11), 289-296.
Gebhardt R: Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta Med. Apr 2002, 68(4), 289-96.
Munter K, Mayer D, Faulstich H: Characterization of a transporting system in rat hepatocytes: studies with competitive and non-competitive inhibitors of phalloidin transport. Biochem Biophys Acta 1986, 860 (1), 91-98.
Faulstich H, Jahn W, Wieland T: Silybin inhibition of amatoxin uptake in Ne perfused rat liver. Arzneimittelforschung/Drug Res. 1980, 30 (I), 3: 452-454.
Koch HP, Bachner J, Loffler E: Silymarin: Patent inhibitor of cyclic AMP phosphodiesterase. Methods Find Exp Clin Pharmacol 1985, 7, 409-413.
Leyon Varghese, Chapla Agarwal, Alpana Tyagi, Rana P. Singh, Rajesh Agarwal: Silibinin Efficacy against Human Hepatocellular Carcinoma. Clin Cancer Res 2005, 11 (1), 8441-8448.
Gazak R, Walterova D, Kren V: Silybin and silymarin – New and emerging applications in medicine. Current Medicinal Chemistry 2007, 14 (3), 1-24.
Tedesco D, Tava A, Galletti S, et al: Effects of silymarin, a natural hepatoprotector, in periparturient dairy cows J Dairy Sci 2004, 87 (7), 2239-2247.
Vojtisek B, Hronova B, Hamrik J, Jankova B: Milk thistle (Silybum marianum, L., Gaertn.) in the feed of ketotic cows. Vet Med (Praha) 1991, 36 (6), 321-.
Tedesco D, Domeneghini C, Sciannimanico D, Tameni M, Steidler S, Galletti S: Silymarin, a possible hepatoprotector in dairy cows: biochemical and histological observations. Journal of Veterinary Medicine Serie A 2004, 51 (2), 85-89.
Grabowicz M, Dorszewski P, Szterk P, Mikołajczak J, Piłat J: Influence of whole crop milk thistle silage on cows’ metabolism in a transition period. Medycyna Wet 2004, 60 (7), 759-762.
Tedesco Doriana, Tameni M, Steidler S, Galletti S, Di Pierro F: Effect of silymarin and its phospholipid complex against AFM[1] excretion.
Tedesco D, Steidler S, Galletti S, Tameni M, Sonzogni O, Ravarotto L: Efficacy of silymarin-phospholipid complex in reducing the toxicity of aflatoxin B[1] in broiler chicks. Poultry Sci 2004, 83 (11), 1839-1843.
Gaweł A, Kotoński B, Madej JA, Mazurkiewicz M: Effect of silimarin on chicken and turkey broilers’ rearing and the production indices of reproduction hen flocks. Medycyna Wet. 2003, 59 (6), 517-520.
Urbanczyk J, Hanczakowska E, Swiatkiewicz M: Herb mixture as an antibiotic substitute in pig feeding. Medycyna Wet 2002, 58 (11), 887- 889.
Thamsborg SM, Jorgensen RJ, Brummerstedt E, Bjerregard J: Putative effect of silymarin on sawfly (arge pullata)-induced hepatotoxicosis in sheep. Vet. Hum. Toxicol. 1996, 38 (2), 89-91.
Oelrichs PB: Sawfly poisoning of cattle Queensland Agricultural Journal 1982, 108, 110-112.
Subramanian M, Vijayakumar G, Thirunavukkarasu PS: Treatment of canine hepatic disorder with silymarin. Indian Vet. J. 2004, 81 (8), 930-932.
Subramanian M, Vijayakumar G, Thirunavukkarasu PS: Comparative evaluation of Silymarin, phospholipids and their combination in the treatment of canine hepatic disorders. Indian Vet. J. 2004, 81 (8), 883-885.
Vijayakumar G, Subramanian M, Srinivasan SR: Efficacy of silymarin as hepatoprotectant in oxytetracycline induced hepatic disorder in dogs. Indian Vet. J 2004, 81 (1), 37-39.
Chon SK, Kim NS: Evaluation of silymarin in the treatment on asymptomatic Giardia infections in dogs. Parasitol Res 2005, 97 (6), 445-51.
Valenzuella A, Garride A: Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994, 27, 105-112.